Johnson & Johnson’s (JNJ) Pharmaceuticals segment comprises the immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolics franchises.

Johnson & Johnson’s 2Q17 Estimates: Pharmaceuticals

Infectious diseases

The infectious diseases franchise consists mainly of HIV products and hepatitis C products. The strong performances of HIV products such as Prezcobix are expected to drive this franchise’s revenue in 2Q17.

On the other hand, the lower sales of hepatitis C products such as Olysio, Sovraid, and Invico due to increased US competition are expected to offset the franchise’s revenue growth in 2Q17.

Cardiovascular and metabolics

The key products in the cardiovascular and metabolics franchise are Xarelto and Invokana. Xarelto is expected to report growth in 2Q17, driven by the increased demand in the US market. Xarelto’s rise in revenue will likely be substantially offset by lower sales of Invokana in 2Q17.


The immunology franchise includes many blockbuster drugs such as Stelara, Simponi and Simponi Aria, and Remicade. Stelara is expected to report strong sales in both the US and international markets in 2Q17, while Simponi and Simponi Aria are expected to report strong sales due to their increased penetration in the US market. Remicade’s sales are expected to offset the growth of the franchise in 2Q17.


The oncology franchise includes drugs such as Zytiga, Imbruvica, and Darzalex. The strong performances of Darzalex and Imbruvica are expected to drive the growth in the oncology franchise’s revenue in 2Q17, while Zytiga’s lower sales are expected to affect the growth of the franchise in 2Q17.


The neuroscience franchise consists of drugs such as Concerta, Invega Sustenna, and Xeplion. The franchise’s Invega sales are expected to fall in 2Q17, and JNJ’s divestiture of the active pharmaceuticals ingredients business in 1Q17 is expected to continue to have a negative effect on its revenue. The franchise’s Xeplion sales are expected to report growth in 2Q17.

To divest risk, investors can consider ETFs such as the Vanguard Healthcare ETF (VHT), which holds ~10.0% of its total assets in Johnson & Johnson. VHT also holds 5.1% in Merck & Co. (MRK), 2.8% in Bristol-Myers Squibb (BMY), and 6.1% in Pfizer (PFE).

Latest articles

On June 25, the soft economic data isn't an isolated case. We have been getting a flurry of dismal data points. The US economy added only 75,000 non-farm jobs in May.

French retail giant Carrefour has agreed to sell an 80% stake in its China operations for ~$705 million to, an Alibaba (BABA) backed company. While China represents a massive opportunity with its almost 1.4 billion population, it has not been an easy market for foreign companies, at least when it comes to retail and e-commerce.

On June 25, US Secretary of Agriculture Sonny Perdue told CNN in an interview that the US-China trade war has impacted US farmers. He said that farmers “are one of the casualties” of the trade war.

25 Jun

Hang Seng and Nikkei 225 Lose amid Trade Worries

WRITTEN BY Mayur Sontakke, CFA, FRM

After rising marginally yesterday, Hong Kong’s Hang Seng Index fell today. The index lost 1.15% to end at 28,185.98. Only seven stocks in the index rose, while 39 declined. Four remained unchanged. Tencent Holdings (TCEHY) was one of the worst performers with a 1.8% fall.

Square (SQ) was absent from the list of the inaugural members of the Libra Association, the entity that will ensure that Facebook’s (FB) Libra cryptocurrency works as intended. Nearly 30 companies have joined the Libra Association.

Kroger (KR) stock fell 2.2% on June 20—the day the company announced its results for the first quarter, which ended on May 25. The negative sentiment for the stock continued.